The MS for Dwyfor Meirionnydd hosts an event at the Senedd, urging greater support for rare diseases, especially in the Welsh ...
Understanding the factors associated with geographic atrophy progression is key to identifying those who may benefit from treatment.
Researchers analyzed longitudinal changes in substructure brain volumes after menopause in women with multiple sclerosis.
Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...
InvestorsHub on MSN
Alterity Therapeutics Shares Edge Higher After Encouraging MSA Trial Results
Shares of Alterity Therapeutics Ltd (NASDAQ:ATHE) climbed 3.3% in premarket trading on Thursday after the company unveiled ...
Investing.com -- Alterity Therapeutics Ltd (NASDAQ:ATHE) stock rose 3.3% in premarket trading Thursday following the company’s presentation of positive data from its Phase 2 clinical trial for ...
Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...
A member of the Senedd has called for urgent action to support people living with rare diseases.
Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –MELBOURNE, Australia and SAN ...
University of California divulges new α-synuclein, amyloid-β protein and MAPT propagation inhibitors
The University of California has synthesized α-synuclein (SNCA) and/or amyloid-β protein and/or microtubule-associated protein tau (PHF-tau; MAPT) propagation inhibitors reported to be useful for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback